268 related articles for article (PubMed ID: 26895104)
1. Quantitative proteomics reveals the novel co-expression signatures in early brain development for prognosis of glioblastoma multiforme.
Yu X; Feng L; Liu D; Zhang L; Wu B; Jiang W; Han Z; Cheng S
Oncotarget; 2016 Mar; 7(12):14161-71. PubMed ID: 26895104
[TBL] [Abstract][Full Text] [Related]
2. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
[TBL] [Abstract][Full Text] [Related]
3. Integration of RNA-Seq and proteomics data identifies glioblastoma multiforme surfaceome signature.
Syafruddin SE; Nazarie WFWM; Moidu NA; Soon BH; Mohtar MA
BMC Cancer; 2021 Jul; 21(1):850. PubMed ID: 34301218
[TBL] [Abstract][Full Text] [Related]
4. MALAT1 is a prognostic factor in glioblastoma multiforme and induces chemoresistance to temozolomide through suppressing miR-203 and promoting thymidylate synthase expression.
Chen W; Xu XK; Li JL; Kong KK; Li H; Chen C; He J; Wang F; Li P; Ge XS; Li FC
Oncotarget; 2017 Apr; 8(14):22783-22799. PubMed ID: 28187000
[TBL] [Abstract][Full Text] [Related]
5. Construction of co-expression modules related to survival by WGCNA and identification of potential prognostic biomarkers in glioblastoma.
Zhou J; Guo H; Liu L; Hao S; Guo Z; Zhang F; Gao Y; Wang Z; Zhang W
J Cell Mol Med; 2021 Feb; 25(3):1633-1644. PubMed ID: 33449451
[TBL] [Abstract][Full Text] [Related]
6. Identification of glioblastoma gene prognosis modules based on weighted gene co-expression network analysis.
Xu P; Yang J; Liu J; Yang X; Liao J; Yuan F; Xu Y; Liu B; Chen Q
BMC Med Genomics; 2018 Nov; 11(1):96. PubMed ID: 30382873
[TBL] [Abstract][Full Text] [Related]
7. Gene expression profile of glioblastoma multiforme invasive phenotype points to new therapeutic targets.
Hoelzinger DB; Mariani L; Weis J; Woyke T; Berens TJ; McDonough WS; Sloan A; Coons SW; Berens ME
Neoplasia; 2005 Jan; 7(1):7-16. PubMed ID: 15720813
[TBL] [Abstract][Full Text] [Related]
8. Quiescent stem cell marker genes in glioma gene networks are sufficient to distinguish between normal and glioblastoma (GBM) samples.
Mukherjee S
Sci Rep; 2020 Jul; 10(1):10937. PubMed ID: 32616845
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive analysis of Reverse Phase Protein Array data reveals characteristic unique proteomic signatures for glioblastoma subtypes.
Patil V; Mahalingam K
Gene; 2019 Feb; 685():85-95. PubMed ID: 30401645
[TBL] [Abstract][Full Text] [Related]
10. Identification of key genes involved in the recurrence of glioblastoma multiforme using weighted gene co-expression network analysis and differential expression analysis.
Ren P; Wang J; Li L; Lin X; Wu G; Chen J; Zeng Z; Zhang H
Bioengineered; 2021 Dec; 12(1):3188-3200. PubMed ID: 34238116
[TBL] [Abstract][Full Text] [Related]
11. Identification of candidate biomarkers for GBM based on WGCNA.
Sun Q; Wang Z; Xiu H; He N; Liu M; Yin L
Sci Rep; 2024 May; 14(1):10692. PubMed ID: 38724609
[TBL] [Abstract][Full Text] [Related]
12. Identification of hub genes and regulatory factors of glioblastoma multiforme subgroups by RNA-seq data analysis.
Li Y; Min W; Li M; Han G; Dai D; Zhang L; Chen X; Wang X; Zhang Y; Yue Z; Liu J
Int J Mol Med; 2016 Oct; 38(4):1170-8. PubMed ID: 27572852
[TBL] [Abstract][Full Text] [Related]
13. LncRNA and mRNA expression profiles of glioblastoma multiforme (GBM) reveal the potential roles of lncRNAs in GBM pathogenesis.
Li Q; Jia H; Li H; Dong C; Wang Y; Zou Z
Tumour Biol; 2016 Nov; 37(11):14537-14552. PubMed ID: 27604987
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 expression and prognostic impact in glioblastoma.
Nduom EK; Wei J; Yaghi NK; Huang N; Kong LY; Gabrusiewicz K; Ling X; Zhou S; Ivan C; Chen JQ; Burks JK; Fuller GN; Calin GA; Conrad CA; Creasy C; Ritthipichai K; Radvanyi L; Heimberger AB
Neuro Oncol; 2016 Feb; 18(2):195-205. PubMed ID: 26323609
[TBL] [Abstract][Full Text] [Related]
15. Gene and microRNA Signatures Are Associated with the Development and Survival of Glioblastoma Patients.
Yang Q; Wang R; Wei B; Peng C; Wang L; Hu G; Kong D; Du C
DNA Cell Biol; 2019 Jul; 38(7):688-699. PubMed ID: 31188028
[TBL] [Abstract][Full Text] [Related]
16. Identification of Prognostic Biomarkers for Glioblastoma Based on Transcriptome and Proteome Association Analysis.
Wang J; Yan S; Chen X; Wang A; Han Z; Liu B; Shen H
Technol Cancer Res Treat; 2022; 21():15330338211035270. PubMed ID: 35538679
[TBL] [Abstract][Full Text] [Related]
17. Four specific biomarkers associated with the progression of glioblastoma multiforme in older adults identified using weighted gene co-expression network analysis.
Yang Y; Chu L; Zeng Z; Xu S; Yang H; Zhang X; Jia J; Long N; Hu Y; Liu J
Bioengineered; 2021 Dec; 12(1):6643-6654. PubMed ID: 34516348
[TBL] [Abstract][Full Text] [Related]
18. Detection of p53 mutations in proliferating vascular cells in glioblastoma multiforme.
Kawasoe T; Takeshima H; Yamashita S; Mizuguchi S; Fukushima T; Yokogami K; Yamasaki K
J Neurosurg; 2015 Feb; 122(2):317-23. PubMed ID: 25415071
[TBL] [Abstract][Full Text] [Related]
19. Multi-analyte network markers for tumor prognosis.
Kim J; Gao L; Tan K
PLoS One; 2012; 7(12):e52973. PubMed ID: 23300836
[TBL] [Abstract][Full Text] [Related]
20. A 63 signature genes prediction system is effective for glioblastoma prognosis.
Zhang Y; Xu J; Zhu X
Int J Mol Med; 2018 Apr; 41(4):2070-2078. PubMed ID: 29393370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
